KCM
MRTX

Kynam Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Kynam Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-499,853
Closed -$18.6M – 35
2023
Q1 		$18.6M Buy
499,853
+308,695
+161% +$13.9M 2.4% 12
2022
Q4 		$8.66M Buy
+191,158
New +$12.4M 1.33% 18

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Kynam Capital Management's MRTX Position: Q2 2023 in Review

Kynam Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 499,853 shares — an estimated $18.6M sold.

Kynam Capital Management first reported a position in MRTX in Q4 2022 and held it in 2 quarters. The position peaked at $18.6M in Q1 2023. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

  • Kynam Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Kynam Capital Management sold 499,853 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $18.6M.
  • Kynam Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Kynam Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $18.6M in Q1 2023.
  • 207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Kynam Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.